Opinion
Video
Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
Panelists discuss how medical professionals consider continuing osimertinib with second-line and subsequent therapies based on disease progression, resistance mechanisms, and patient response. It may be combined with other agents or switched depending on clinical trials, biomarkers, and overall treatment goals to optimize outcomes.
Video content above is prompted by the following:
What are your thoughts on continuing osimertinib treatment with second-line and subsequent therapies?
Latest CME
View All
Video
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
May 14th 2025 - May 15th 2026
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
May 13th 2025 - Jun 18th 2025
online-activity
Video
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
May 9th 2025 - Jun 14th 2025
online-activity
Related Content
.jpg?fit=crop&auto=format)
